Biostage reduces CEO milestone stock options from 488,256 to 267,616 shares

Harvard Apparatus Regenerative Technology, Inc.

Amendment corrects Milestone Grant for CEO Junli He from 488,256 to 267,616 shares.
Each vesting increment reduced from 244,128 to 133,808 shares, still two tranches.
Effective retroactively to March 14, 2023; no other changes to employment agreement.
Reduction lowers potential dilution from milestone options by approximately 45%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.